Drugs in MeSH Category Antifibrinolytic Agents

« Back to Dashboard

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ani Pharms	AMINOCAPROIC ACID	aminocaproic acid	TABLET;ORAL	211629-001	Dec 14, 2020		DISCN	No	No
Amneal	AMINOCAPROIC ACID	aminocaproic acid	TABLET;ORAL	212492-001	Nov 26, 2019	AB	RX	No	No
Hospira	AMINOCAPROIC ACID IN PLASTIC CONTAINER	aminocaproic acid	INJECTABLE;INJECTION	070010-001	Mar 9, 1987	AP	RX	No	Yes
Hikma	AMICAR	aminocaproic acid	SOLUTION;ORAL	015230-002	Approved Prior to Jan 1, 1982	AA	RX	Yes	No

Market Dynamics and Patent Landscape for Antifibrinolytic Agents

Last updated: March 4, 2026

What are the key drugs in the antifibrinolytic agents class?

The primary antifibrinolytic drugs are:

• Tranexamic Acid (TXA): Widely used for bleeding control in trauma, surgery, and menorrhagia.
• Epsilon-Aminocaproic Acid (EACA): Used for massive hemorrhage during surgery.
• Aminocaproic Acid derivatives: Under investigation for specific indications.

How does the current market size evolve?

Global antifibrinolytic drugs market was valued at approximately USD 350 million in 2022. It is projected to register a compound annual growth rate (CAGR) of around 4.5% from 2023 to 2030, reaching over USD 500 million.

Market drivers:

• Rise in trauma-related bleeding cases.
• Increasing utilization in cardiac surgeries.
• Growing approval for off-label uses.
• Development of new formulations, including extended-release options.

Market constraints:

• Availability of alternative hemostatic agents such as recombinant factor concentrates.
• Concerns over adverse events, notably thromboembolic risks associated with TXA.
• Regulatory restrictions in certain countries.

How does the patent landscape look for key drugs?

Tranexamic Acid

• Patent expiration: Original patents expired around 2008-2010.
• New formulations: Patent activities largely focus on new delivery systems, such as topical formulations, nasal sprays, and extended-release tablets.
• Recent patent filings: Companies like Pfizer and GlaxoSmithKline have filed patents related to formulations with improved bioavailability and stability.

Epsilon-Aminocaproic Acid

• Patent status: Patents expired in the early 2000s.
• Innovation focus: Limited recent patent activity; mostly off-patent generics dominate the market.

Off-patent landscape:

• Generics hold a dominant position, with multiple suppliers offering non-branded versions.
• Innovator companies focus on combination therapies and novel delivery methods to extend market exclusivity.

Who are the market players?

Major players include:

• Pfizer: Produces generic TXA, with ongoing patents on specific formulations.
• GlaxoSmithKline: Historical patent activity on novel formulations.
• Bayer: Involved in development of topical and targeted delivery systems.
• Pfizer and Mylan: Key suppliers of generic formulations.

Industry also witnesses the emergence of biotech firms exploring biosynthetic variants and combination therapies.

What are recent patent filing trends?

Between 2015 and 2022:

• Patent filings related to extended-release formulations increased by approximately 35%.
• Patent applications focusing on topical applications rose by 20%.
• Delivery system innovations (e.g., nasal sprays, patch-based systems) accounted for around 15% of filings.

Key patent areas:

• Formulation enhancements for bioavailability.
• Delivery mechanism innovations.
• Combination use with other hemostatic agents.
• Stability and shelf-life improvements.

How do regulatory policies impact R&D?

• The US Food and Drug Administration (FDA) classifies TXA under approved indications for specific surgical and bleeding conditions.
• The European Medicines Agency (EMA) grants conditional approvals for new formulations.
• Regulatory pathways favor generic manufacturers due to patent expirations, but new formulations requiring extensive clinical trials face longer approval timelines.

What is the outlook for innovation and market entries?

• New formulations aiming to reduce thromboembolic risks are under development.
• Biotech startups explore biosynthetic variants with improved safety profiles.
• Market entry barriers are lower for generics; innovation focuses on delivery systems and combinational therapies.

Key Takeaways

• The antifibrinolytic agent market is mature, with key drugs primarily off-patent.
• Patent activity centers on formulation improvements; original patents expired over a decade ago.
• The market is projected to grow modestly driven by surgical and trauma-related applications.
• Innovation emphasizes alternative delivery routes and enhanced safety profiles.
• Regulatory frameworks influence R&D focus, favoring both generics and novel formulations.

FAQs

1. What are the main challenges in developing new antifibrinolytic agents?
   Challenges include balancing efficacy with thromboembolic risk and navigating lengthy, costly clinical trials for new formulations.

2. Are there any promising biosynthetic or biologic alternatives?
   Biosynthetic variants are under early-stage investigation but are not yet commercially available.

3. How do patent expirations affect market competition?
   Once key patents expire, generic manufacturers dominate, increasing price competition but reducing incentives for innovation.

4. What role do regulatory policies play in R&D?
   They influence the pace of development, especially for new formulations requiring extensive safety and efficacy data.

5. What future market segments could see growth?
   Topical applications, nasal sprays, and combination therapies are likely growth areas, driven by safety improvements and new delivery systems.

---

References

[1] MarketsandMarkets. (2023). Antifibrinolytic Agents Market by Product, Application, and Region. Market Research Future.